Dermata Therapeutics
NASDAQ: DRMASan Diego, US · Founded 2021 · Delaware corporation
Founders & leadership
MB
Maria Bedoya Toro MuneraExecutive
GP
Gerald ProehlExecutive
KK
Kyri K. Van HooseExecutive
CJ
Christopher J. NardoExecutive
TI
Tom InsleyChief Financial Officer
Board
BB
Brittany BradrickBoard director
MF
Mary FisherBoard director
KS
Kathleen ScottBoard director
SM
Steven MentoBoard director
WW
Wendell WierengaBoard director
AS
Andrew SandlerBoard director
DH
David HaleBoard director
Reported raises · per SEC filings
Form D private placements$26.3M disclosed across 8 of 9 rounds · 2014–2025
▶$4.1MraisedJan 2026 · 14 investors · BiotechnologyRule 506(b)
▶$4.1MraisedJan 2026 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Maria Bedoya Toro MuneraExecutive Officer
- Mary FisherDirector
- Kathleen ScottDirector
- Steven MentoDirector
- Wendell WierengaDirector
- Gerald ProehlExecutive Officer, Director
- Andrew SandlerDirector
- Kyri K. Van HooseExecutive Officer
- David HaleDirector
- Christopher J. NardoExecutive Officer
- Brittany BradrickDirector
- Offering amount
- $4.1M
- Amount sold
- $4.1M
- Sales commissions
- $342.5K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$2.5MraisedFeb 2025 · 8 investors · Other TechnologyRule 506(b)
▶$2.5MraisedFeb 2025 · 8 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Gerald ProehlExecutive Officer, Director
- Brittany BradrickDirector
- Christopher J. NardoExecutive Officer
- Maria Bedoya Toro MuneraExecutive Officer
- Steven MentoDirector
- Mary FisherDirector
- Kathleen ScottDirector
- Kyri K. Van HooseExecutive Officer
- Wendell WierengaDirector
- Andrew SandlerDirector
- David HaleDirector
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- Sales commissions
- $174.8K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$3.5MraisedSep 2024 · 1 investors · Other TechnologyRule 506(b)
▶$3.5MraisedSep 2024 · 1 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Steven MentoDirector
- Gerald ProehlExecutive Officer, Director
- Andrew SandlerDirector
- Wendell WierengaDirector
- Kathleen ScottDirector
- Kyri K. Van HooseExecutive Officer
- Brittany BradrickDirector
- David HaleDirector
- Maria Bedoya Toro MuneraExecutive Officer
- Mary FisherDirector
- Christopher J. NardoExecutive Officer
- Offering amount
- $3.5M
- Amount sold
- $3.5M
- Sales commissions
- $345K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶Undisclosed amountofferedJun 2023 · 2 investors · Other TechnologyRule 506(b)
▶Undisclosed amountofferedJun 2023 · 2 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Kyri K. Van HooseExecutive Officer
- Kathleen ScottDirector
- Mary FisherDirector
- David HaleDirector
- Christopher J. NardoExecutive Officer
- Wendell WierengaDirector
- Maria Bedoya Toro MuneraExecutive Officer
- Steven MentoDirector
- Brittany BradrickDirector
- Andrew SandlerDirector
- Gerald T. ProehlDirector, Executive Officer
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- May 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$3MraisedDec 2020 · 37 investors · BiotechnologyRule 506(b)
▶$3MraisedDec 2020 · 37 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Hale BioPharma Ventures, LLCPromoter, Executive Officer
- David F. HaleExecutive Officer, Director, Promoter
- Wendell WierengaDirector
- Tom InsleyExecutive Officer
- Chris NardoExecutive Officer
- Gerald T. ProehlDirector, Promoter, Executive Officer
- Amount sold
- $3M
- First sale
- Jul 2020
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$5MraisedMay 2018 · 49 investors · BiotechnologyRule 506(b)
▶$5MraisedMay 2018 · 49 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chris NardoExecutive Officer
- David F. HaleExecutive Officer, Director, Promoter
- Gerald T. ProehlDirector, Promoter, Executive Officer
- Tom InsleyExecutive Officer
- Hale BioPharma Ventures, LLCPromoter, Executive Officer
- Amount sold
- $5M
- First sale
- Nov 2016
- Incorporated
- Limited Liability Company, Delaware, 2014
- Federal exemptions
- 06b
▶$6.9MraisedMay 2018 · 49 investors · BiotechnologyRule 506(b)
▶$6.9MraisedMay 2018 · 49 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David F. HaleExecutive Officer, Director, Promoter
- Chris NardoExecutive Officer
- Gerald T. ProehlDirector, Promoter, Executive Officer
- Tom InsleyExecutive Officer
- Hale BioPharma Ventures, LLCPromoter, Executive Officer
- Amount sold
- $6.9M
- First sale
- Jan 2016
- Incorporated
- Limited Liability Company, Delaware, 2014
- Federal exemptions
- 06b
▶$651.3KraisedJun 2015 · 7 investors · BiotechnologyRule 506(b)
▶$651.3KraisedJun 2015 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David F. HaleExecutive Officer, Director, Promoter
- Chris NardoExecutive Officer
- Hale BioPharma Ventures, LLCPromoter, Executive Officer
- Tom InsleyExecutive Officer
- Gerald T. ProehlDirector, Promoter
- Amount sold
- $651.3K
- First sale
- Apr 2015
- Incorporated
- Limited Liability Company, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- How much funding has Dermata Therapeutics raised?
- Dermata Therapeutics has disclosed $26.3M raised across 8 of its 9 known rounds.
- Where is Dermata Therapeutics headquartered?
- Dermata Therapeutics is headquartered in San Diego, US.